Top brokers name 3 ASX shares to sell next week

Brokers aren't feeling overly positive on these shares…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Once again, a large number of broker notes hit the wires last week. Some of these notes were positive and some were bearish.

Three sell ratings that caught my eye are summarised below. Here's why top brokers think investors ought to sell these shares next week:

Fortescue Metals Group Limited (ASX: FMG)

According to a note out of UBS, its analysts have downgraded this mining giant's shares to a sell rating and cut the price target on them to $15.00. The broker made the move on the belief that iron ore prices will continue to fall in the coming months. UBS suspects that prices could fall to between US$70 and US$80 a tonne. This would weigh on Fortescue's free cash flow and dividends. The Fortescue share price ended the week at $15.27.

Magellan Financial Group Ltd (ASX: MFG)

Another note out of UBS reveals that its analysts have downgraded this fund manager's shares to a sell rating and cut the price target on them materially to $35.00. UBS notes that Fortescue is experiencing fund outflows at a time when its investment performance is lagging and pressure on its higher than average fees is growing. The Magellan share price was fetching $15.27 at Friday's close.

Xero Limited (ASX: XRO)

Analysts at Macquarie have retained their underperform rating and $130.00 price target on this cloud accounting company's shares. This follows news that rival Intuit is acquiring email marketing company Mailchimp. Macquarie is concerned that Intuit could remove Mailchimp from Xero's ecosystem. If it does, it suspects that some subscribers may switch to Intuit's Quickbooks in order to retain access to the app. In addition, it believes the acquisition strengthens Intuit's offering and could support its global expansion. The Xero share price ended the week at $153.34.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Xero. The Motley Fool Australia owns shares of and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
Broker Notes

Are CBA shares still a good buy for passive income?

A leading analyst delivers his verdict on CBA’s passive income appeal.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Morgans names 2 ASX shares to buy and 1 to accumulate

What is the broker recommending investors do with these shares?

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

2 ASX 200 shares to buy ahead of anticipated rally: expert

After a 9.1% drop between 27 February and 23 March, the ASX 200 reversed course last Tuesday.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Broker Notes

Bell Potter says this ASX 200 stock can rise 38% and pay a 6% dividend yield

Major upside and a generous dividend yield could be on offer with this name.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Broker Notes

Is this ASX defence stock the next DroneShield?

Bell Potter thinks this stock could be the next to rocket. Let's find out why.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Broker Notes

This ASX healthcare stock could almost double in value according to Bell Potter

The broker believes this stock is making major breakthroughs.

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »